[Bosentan for treatment of heart failure].
Yoshimoto
Takanobu
T
Department of Clinical and Molecular Endocrinology, Tokyo Medical and Dental University Graduate School.
Hirata
Yukio
Y
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D000077300:Bosentan; D002986:Clinical Trials as Topic; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000502:physiology; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D020257:Ventricular Remodeling
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D013449:Sulfonamides; D000077300:Bosentan